GenSight Biologics SA 2018 IR
The report highlights GenSight Biologics' progress in 2018, focusing on its lead gene therapy product candidates, GS010 for Leber Hereditary Optic Neuropathy (LHON) and GS030 for Retinitis Pigmentosa (RP). The company reported positive Phase III clinical trial results for GS010 and initiated the Phase I/II PIONEER trial for GS030. Financially, GenSight secured up to €12 million in bond financing from Kreos Capital and completed a €9 million capital increase with Sofinnova and 3SBio. The company also reported on its corporate social responsibility, noting a workforce of 33 employees with 55% female representation.
Company: GenSight Biologics SA
Sector: Professional & technical services
Country: France
Year: 2018
Type: IR
Pages: 264
Back to company
GenSight Biologics SA
Universal Registration Document
The report highlights GenSight Biologics' progress in 2018, focusing on its lead gene therapy product candidates, GS010 for Leber Hereditary Optic Neuropathy (LHON) and GS030 for Retinitis Pigmentosa (RP). The company reported positive Phase III clinical trial results for GS010 and initiated the Phase I/II PIONEER trial for GS030. Financially, GenSight secured up to €12 million in bond financing from Kreos Capital and completed a €9 million capital increase with Sofinnova and 3SBio. The company also reported on its corporate social responsibility, noting a workforce of 33 employees with 55% female representation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Published
Dec 20, 2019
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Workplace Fatalities
Employees